Acorda Therapeutics, Inc. (NASDAQ:ACOR) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07Submission of Matters to a Vote of Security Holders.

Acorda Therapeutics, Inc. (the Company) held its Annual Meeting
of Stockholders on May 31, 2017 (the Annual Meeting) at the
Residence Inn by Marriott, 7 Executive Boulevard, Yonkers, NY
10701. 41,624,334 shares of the Companys common stock, or 89.02%
of the shares of the Companys common stock issued and outstanding
on the record date for the Annual Meeting, were present in person
or represented by proxy at the Annual Meeting. Summarized below
are descriptions of the proposals voted on at the Annual Meeting
and the final results of such voting:

Proposal One: Election of directors

As described in the Companys 2017 Proxy Statement, the Companys
Board of Directors nominated three individuals to serve as Class
III directors for a term to expire on the date of the Companys
2020 Annual Meeting of Stockholders or until their successors are
duly elected and qualified. All of such nominees were elected by
a plurality vote (and also received a majority vote, for purposes
of the majority vote provisions of the Companys Bylaws), as
follows:

Proposal Two: Ratification of appointment of independent auditors

The Companys stockholders ratified the appointment of Ernst Young
LLP as the Companys independent auditors for the fiscal year
ending December 31, 2017, by the following vote:

Proposal Three: Advisory (non-binding) vote to approve named
executive officer compensation

The Companys stockholders voted, in an advisory, non-binding
manner, to approve the compensation of the Companys Named
Executive Officers as disclosed in the Companys 2017 Proxy
Statement to the compensation disclosure rules of the Securities
and Exchange Commission, including the Compensation Discussion
and Analysis, the executive compensation tables and the related
footnotes and narrative accompanying the tables (the say-on-pay
vote). The Companys stockholders voted as follows to approve such
executive compensation to the say-on-pay vote:

Proposal Four: Advisory (non-binding) vote on the frequency of
executive compensation votes

The Companys stockholders voted as follows in an advisory,
non-binding manner, on the frequency of future say-on-pay votes:

The frequency of holding say-on-pay votes every year, which was
the recommendation of the Companys Board of Directors, received
the greatest number of votes from the Companys stockholders.With
the support of these voting results, the Board of Directors has
decided that the Company will hold future say-on-pay votes every
year until the next required vote on the frequency of stockholder
votes on the compensation of the Companys executives.

About Acorda Therapeutics, Inc. (NASDAQ:ACOR)

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson’s disease, chronic post-stroke walking deficits and migraine.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Recent Trading Information

Acorda Therapeutics, Inc. (NASDAQ:ACOR) closed its last trading session down -0.30 at 13.80 with 1,110,747 shares trading hands.